Skip to main content
. 2019 Dec 9;10(12):936. doi: 10.1038/s41419-019-2177-x

Fig. 5. The expression of LCN2 is associated with the poor prognosis of patients with OSCC.

Fig. 5

a Immunohistochemical analysis of LCN2 expression (grade 0) in well-differentiated OSCC; b Immunohistochemical analysis of LCN2 expression (grade 1) in well-differentiated OSCC; c Immunohistochemical analysis of LCN2 expression (grade 2) in moderately differentiated OSCC; d Immunohistochemical analysis of LCN2 expression (grade 3) in poorly differentiated OSCC; e Negative LCN2 expression in ANC tissue; f Positive LCN2 expression in lymphatic metastases; g Kaplan–Meier estimates of the overall survival of patients with LCN2 expression; h Kaplan–Meier estimates of the overall survival of patients with LCN2 expression who experienced recurrence (scale bar: 20 μm).